Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Microbix Biosystems Inc T.MBX

Alternate Symbol(s):  MBXBF

Microbix Biosystems Inc. develops and commercializes biological and technological solutions for human health and wellbeing. It enables the commercialization of diagnostic assays by making a range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Its segments include development, manufacturing and sales of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows and viral transport medium to enable collection of patient test samples and, and development and commercialization of novel and proprietary products or technologies, such as Kinlytic. Its Kinlytic urokinase is a biologic thrombolytic drug used to treat blood clots.


TSX:MBX - Post by User

Comment by wizzdumbon Dec 28, 2021 8:12am
185 Views
Post# 34265078

RE:iA Capital Markets: Buy rating and $1.70 target for MBX

RE:iA Capital Markets: Buy rating and $1.70 target for MBX

Her FY2022 estimates are on the very low end of estimates from the company although I'd be happy to see her price forecast come to fruition in the next few months.

Will almost certainly see KRC update this week or next and perhaps also from ESpace. 

Will be interesting to see what kind of action we get this week since VTM announcement came out on shortened trading day right before Christmas. Probably more attention this week but not back to normal until next. Still a few days for a surprise "photo finish" Kinlytic announcement but likely will have to wait a little bit still. 

<< Previous
Bullboard Posts
Next >>